RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Article Summary
HOLD- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported the grant of 65,886 restricted stock units of Ultragenyx Pharmaceutical's common stock to 39 newly hired non-executive officers under Nasdaq Listing Rule 5635(c)(4) granted under the Ultragenyx Employment Inducement Plan with a grant date of July 16, 2026 as an inducement material to new employees entering into employment with the biopharmaceutical company.
- Ultragenyx Pharmaceutical is focused on the development and commercialization of novel therapies for rare and ultra-rare diseases with a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating underlying disease.
- The awards were approved by the compensation committee of the board of directors and granted under NasDAQ Rule 5634(c), with 25% of the underlying shares vesting on each anniversary of grant date subject to employee being continuously employed by the company as of such vesting dates, and vesting over four years.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 13.3% | 25% | 50.0 ptsMeets Minimum (13.3%) - Passes screener |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 98.0% | 20% | 100.0 ptsMassive Upside (98.0%) - Target: $53.26 vs Current: $26.90 |
| Gross Margin % ? | 78.5% | 15% | 100.0 ptsExceptional (78.5%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -32.6% | 15% | 80.0 ptsSolid Dip (-32.6%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About RARE
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
- Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome.
- It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease.
- The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona.
- Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.